Corcept Therapeutics Incorporated (CORT) - Total Assets
Based on the latest financial reports, Corcept Therapeutics Incorporated (CORT) holds total assets worth $814.88 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CORT cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Corcept Therapeutics Incorporated - Total Assets Trend (2000–2025)
This chart illustrates how Corcept Therapeutics Incorporated's total assets have evolved over time, based on quarterly financial data. Explore CORT long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Corcept Therapeutics Incorporated - Asset Composition Analysis
Current Asset Composition (December 2025)
Corcept Therapeutics Incorporated's total assets of $814.88 Million consist of 58.0% current assets and 42.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.4% |
| Accounts Receivable | $59.79 Million | 7.2% |
| Inventory | $12.87 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Corcept Therapeutics Incorporated's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Corcept Therapeutics Incorporated (CORT) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Corcept Therapeutics Incorporated's current assets represent 58.0% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 14.4% of total assets in 2025, down from 95.7% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 7.2% of total assets.
Corcept Therapeutics Incorporated Competitors by Total Assets
Key competitors of Corcept Therapeutics Incorporated based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
Corcept Therapeutics Incorporated - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.86 | 3.07 | 9.06 |
| Quick Ratio | 2.77 | 2.96 | 8.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $276.85 Million | $295.44 Million | $365.87 Million |
Corcept Therapeutics Incorporated - Advanced Valuation Insights
This section examines the relationship between Corcept Therapeutics Incorporated's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.80 |
| Latest Market Cap to Assets Ratio | 6.71 |
| Asset Growth Rate (YoY) | -0.5% |
| Total Assets | $836.65 Million |
| Market Capitalization | $5.61 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Corcept Therapeutics Incorporated's assets at a significant premium (6.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Corcept Therapeutics Incorporated's assets decreased by 0.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Corcept Therapeutics Incorporated (2000–2025)
The table below shows the annual total assets of Corcept Therapeutics Incorporated from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $836.65 Million | -0.46% |
| 2024-12-31 | $840.55 Million | +35.24% |
| 2023-12-31 | $621.52 Million | +6.53% |
| 2022-12-31 | $583.43 Million | +37.68% |
| 2021-12-31 | $423.76 Million | -25.88% |
| 2020-12-31 | $571.73 Million | +38.66% |
| 2019-12-31 | $412.31 Million | +32.28% |
| 2018-12-31 | $311.69 Million | +41.33% |
| 2017-12-31 | $220.54 Million | +220.77% |
| 2016-12-31 | $68.75 Million | +32.38% |
| 2015-12-31 | $51.94 Million | +49.98% |
| 2014-12-31 | $34.63 Million | -45.10% |
| 2013-12-31 | $63.08 Million | -36.39% |
| 2012-12-31 | $99.17 Million | +148.95% |
| 2011-12-31 | $39.83 Million | +58.67% |
| 2010-12-31 | $25.10 Million | +2.42% |
| 2009-12-31 | $24.51 Million | +23.95% |
| 2008-12-31 | $19.77 Million | +11.45% |
| 2007-12-31 | $17.74 Million | +79.20% |
| 2006-12-31 | $9.90 Million | -67.16% |
| 2005-12-31 | $30.16 Million | -36.87% |
| 2004-12-31 | $47.77 Million | +305.50% |
| 2003-12-31 | $11.78 Million | -45.95% |
| 2002-12-31 | $21.80 Million | -10.16% |
| 2001-12-31 | $24.26 Million | +2219.22% |
| 2000-12-31 | $1.05 Million | -- |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more